| Dr James L Chambers, DO | |
|
5100 Gateway Ctr, Flint, MI 48507-3927 | |
| (810) 733-6480 | |
| (810) 733-6483 |
| Full Name | Dr James L Chambers |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 46 Years |
| Location | 5100 Gateway Ctr, Flint, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295722288 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 5101008059 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mclaren Flint | Flint, MI | Hospital |
| Hurley Medical Center | Flint, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cardiology Institute Of Michigan Pllc | 3173510112 | 6 |
News Archive
Registration is open for the 10th annual Run for Her® 5K Run and Friendship Walk, one of the nation's premier events to raise public awareness and research funds for the fight against ovarian cancer.
Because Americans spend more per capita on health care than residents of any country, debate has rumbled on for years about whether all that investment yields sufficient results. Now a newly published study with a distinctive design, led by an MIT health care scholar, shows that increased spending on emergency care does, in fact, produce better outcomes for patients.
Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.
› Verified 7 days ago
| Entity Name | Cardiology Institute Of Michigan Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437127297 PECOS PAC ID: 3173510112 Enrollment ID: O20040429001344 |
News Archive
Registration is open for the 10th annual Run for Her® 5K Run and Friendship Walk, one of the nation's premier events to raise public awareness and research funds for the fight against ovarian cancer.
Because Americans spend more per capita on health care than residents of any country, debate has rumbled on for years about whether all that investment yields sufficient results. Now a newly published study with a distinctive design, led by an MIT health care scholar, shows that increased spending on emergency care does, in fact, produce better outcomes for patients.
Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James L Chambers, DO 5100 Gateway Ctr, Flint, MI 48507-3927 Ph: (810) 733-6480 | Dr James L Chambers, DO 5100 Gateway Ctr, Flint, MI 48507-3927 Ph: (810) 733-6480 |
News Archive
Registration is open for the 10th annual Run for Her® 5K Run and Friendship Walk, one of the nation's premier events to raise public awareness and research funds for the fight against ovarian cancer.
Because Americans spend more per capita on health care than residents of any country, debate has rumbled on for years about whether all that investment yields sufficient results. Now a newly published study with a distinctive design, led by an MIT health care scholar, shows that increased spending on emergency care does, in fact, produce better outcomes for patients.
Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.
› Verified 7 days ago
Vidya Sagar Kollu, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: G3230 Beecher Rd, Suite 2, Flint, MI 48532 Phone: 810-342-5800 Fax: 810-342-5810 | |
Dr. Mohamad Monir Khoulani, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5080 Villa Linde Pkwy, Unit 4, Flint, MI 48532 Phone: 810-720-5440 Fax: 810-720-4670 | |
Russell Diponio, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4444 W Bristol Rd Ste 150, Flint, MI 48507 Phone: 810-230-9500 Fax: 810-230-0169 | |
Muhammad Bakleh, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5040 Villa Linde Pkwy, Flint, MI 48532 Phone: 810-230-0788 | |
Dr. Haymanot Y Gebre, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: G3230 Beecher Rd Ste 2, Flint, MI 48532 Phone: 810-342-5800 Fax: 810-342-5810 | |
Dr. Donald J Hardman, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3499 S Linden Rd Ste 2, Flint, MI 48507 Phone: 810-820-8121 Fax: 810-820-8335 | |
Hameem Changezi, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5084 Villa Linde Pkwy, Suite 6, Flint, MI 48532 Phone: 810-600-3399 Fax: 810-600-3398 |